Duration of IWG 2000-defined¹³  RBC-TI in patients randomized to lenalidomide (LEN) 10 mg or 5 mg (mITT population). Figure represents patients who achieved RBC-TI during the double-blind phase of the study. For duration of RBC-TI, data are included until the last date with available information on transfusions. This date is indicated as censored for patients who died or who remain RBC-TI at data cut-off. Median duration of RBC transfusion follow-up for all treatment groups combined was 1.55 years (RBC transfusion follow-up for ≥ 1, ≥ 2, and ≥ 3 years was available for 85, 54, and 9 patients, respectively).